Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other neoplasm 1Other hematologic neoplasm 1Lymphoid 1Endocrine 1Dermatologic 1Classical hematology 1

Conditions

Weight Gain 1Overweight 1Multiple Endocrine Neoplasia Type 1 1

Interventions

lutetium Lu 177 dotatate 36Everolimus 32pembrolizumab 24Temozolomide 21Magnetic Resonance Spectroscopy 21Nivolumab 18lenvatinib 17gallium Ga 68 dotatate 16cabozantinib 15Cisplatin 15lanreotide 143-Iodobenzylguanidine 14Capecitabine 13trametinib 12dabrafenib 12Bevacizumab 12Octreotide 11Surveys and Questionnaires 10Surgical Procedures, Operative 10Sunitinib 10Radiosurgery 10Positron Emission Tomography Computed Tomography 10Blood Specimen Collection 10Sorafenib 9Paclitaxel 9Ipilimumab 9Carboplatin 9surufatinib 8Etoposide 8Doxorubicin 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Sucrose × Endocrine × Clear all
NCT04804397 2021-03-18

Effects of Sucrose Added Blind to the Diet Over Eight Weeks on Body Mass and Weight in Men

University of Hull

Phase NA Completed
80 enrolled
Endocrine

Weight Gain, Multiple Endocrine Neoplasia Type 1, Overweight

Data powered by HemOnc (CC BY 4.0) Colophon âš¡